Indigenous Men Less Likely to Receive PSA Testing
Medically reviewed by Drugs.com.
By Elana Gotkine HealthDay Reporter
MONDAY, July 10, 2023 -- Indigenous men are less likely to receive prostate-specific antigen (PSA) testing and are more likely to be diagnosed with higher-risk prostate cancer, according to a study published online July 10 in Cancer.
Alex Kiciak, M.D., from the University of Alberta in Edmonton, Canada, and colleagues conducted an observational cohort study of men diagnosed with prostate cancer between June 2014 and October 2022 to examine disparities between Indigenous and non-Indigenous men. Data were examined for 1,444,947 men.
The researchers found that men in Indigenous communities were less likely than those outside of Indigenous communities to have PSA testing performed (32 versus 46 PSA tests per 100 men aged 50 to 70 within one year). Of the 6,049 men diagnosed with prostate cancer, Indigenous men had higher-risk disease characteristics than non-Indigenous men, including a higher proportion with PSA ≥10 ng/ml (48 versus 30 percent), TNM stage ≥T2 (65 versus 47 percent), and Gleason grade group ≥2 (79 versus 64 percent). Indigenous men had a higher risk of developing prostate cancer metastases than non-Indigenous men over a median follow-up of 40 months (hazard ratio, 2.3).
"The findings are significant because they identify Indigenous men as a population at risk for more aggressive prostate cancer and potentially worse survival," a coauthor said in a statement. "Key infrastructure changes, including better access to primary care physicians, may help improve prostate cancer screening and identify men at earlier, and curable, stages of the disease."
Several authors disclosed ties to the pharmaceutical industry.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted July 2023
Read this next
AI-Assisted Contours Superior to Cognitively Defined Prostate Cancer Contours
WEDNESDAY, July 3, 2024 -- Artificial intelligence (AI)-assisted definition of prostate cancer contours reduces underestimation of the extent of prostate cancer, according to a...
Mean Cost of Bringing New Drug to U.S. Market Is $879.3 Million
TUESDAY, July 2, 2024 -- The mean cost of developing a new drug for the U.S. market is estimated to be $879.3 million when both drug development failure and capital costs are...
Patient–Primary Care Provider Language Concordance Tied to Better Outcomes
TUESDAY, July 2, 2024 -- Patient-family physician language concordance is associated with a lower risk for adverse outcomes, according to a study published online June 3...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.